Blog

Arrow Exploration Corp. (LSE:AXL) has brought the Mateguafa HZ12 appraisal well into production at Colombia’s Tapir Block, adding restricted gross output of approximately 564 barrels of oil per day. The company said the well confirmed multiple hydrocarbon-bearing zones within the Carbonera C9 and C7 formations.

The well was completed on schedule and below budget, helping support gross corporate production of around 5,000 barrels of oil equivalent per day. Arrow also highlighted its strong financial position, reporting cash holdings of US$24.2 million and no debt, despite temporarily shutting in its Pepper gas field in Alberta because of weak gas prices.

Icaco Exploration Well and Tapir Workovers Target Further Growth

In addition to the Mateguafa development, the company has started drilling the Icaco-1 exploration well from the Icaco pad and is preparing a series of workover operations on the Tapir block aimed at increasing production through recompletions.

Management said discussions regarding an extension of the Tapir block contract remain constructive. The company believes ongoing success at both Mateguafa and the Icaco prospect further strengthens Arrow’s growth outlook within Colombia’s Llanos Basin and could support future development programmes and sustained production increases.

More about Arrow Exploration Corp

Arrow Exploration Corp. is a publicly traded oil and gas producer focused on underdeveloped, high-growth assets across Colombia’s Llanos, Middle Magdalena Valley and Putumayo basins. The company operates a predominantly Brent-linked light oil portfolio characterised by high working interests and low royalty exposure, and its shares trade on both London’s AIM market and the TSX Venture Exchange under the ticker AXL.

Airtel Africa (LSE:AAF) delivered strong results for the year ended 31 March 2026, supported by increasing demand for mobile data and digital financial services across its operating markets. The company’s customer base grew 10.5% to 183.5 million users, while data subscribers increased 14.8% and Airtel Money customers rose 21.3%.

The growth in digital adoption also contributed to higher data consumption and a 49% increase in mobile money transaction values during the year.

Revenue and Profitability Strengthen Across Key Segments

Group revenue increased 24.0% in constant currency terms, or 29.5% on a reported basis, reaching $6.4 billion. Data services became the company’s largest revenue contributor, while mobile money operations also recorded strong expansion.

Underlying EBITDA rose 30.4% in constant currency to $3.2 billion, helping margins improve to 49.3%. Profit after tax climbed sharply to $813 million, supporting a 9.2% increase in the annual dividend. Airtel Africa also increased capital expenditure to expand network infrastructure, home broadband capabilities and data centre capacity, although management noted that rising energy costs could create near-term pressure on margins.

Strong Cash Generation Balanced by Leverage and Technical Weakness

Airtel Africa’s outlook continues to benefit from strong operating profitability and healthy cash flow generation, supported by a positive earnings outlook and improving financing metrics discussed during its latest results presentation.

However, the company still faces challenges linked to balance sheet leverage and historical earnings volatility. Technical indicators also remain relatively weak, with the shares trading below key moving averages, while valuation metrics are less supportive due to a relatively high price-to-earnings ratio and only a modest dividend yield.

More about Airtel Africa Plc

Airtel Africa Plc is a major telecommunications and mobile money services provider operating across 14 countries in sub-Saharan Africa. The company delivers integrated mobile voice, data and digital financial services, with a strategic focus on improving customer experience while expanding digital and financial inclusion throughout its markets.

SRT Marine Systems (LSE:SRT) has been awarded a £5 million one-year support agreement with a long-standing sovereign customer to provide technical support and data services for an existing maritime domain awareness deployment. The contract covers the period from January through December 2026 and represents the customer’s second consecutive annual support agreement with the company.

SRT said the increased value of the deal reflects growing usage of the system and highlights the platform’s expanding role in daily maritime surveillance operations.

Recurring Revenue Opportunity Expands Through Sovereign Partnership

The latest agreement is larger than the equivalent contract signed in the previous year and is expected to contribute to a growing stream of recurring support revenues as the customer continues expanding its SRT-MDA system through additional future projects.

Management described the deal as further evidence of SRT’s long-term business model, which combines multiple recurring revenue streams with strategic sovereign partnerships. The company believes the relationship demonstrates strong growth potential while reinforcing its position within the high-value digital maritime surveillance market serving government customers.

Cash Flow and Valuation Concerns Continue to Weigh on Outlook

Despite strong revenue growth and improving operational efficiency, SRT Marine Systems’ outlook remains affected by weaker cash flow performance. Technical indicators are also currently negative, with momentum remaining weak, although the shares may be approaching oversold territory.

Valuation metrics remain stretched due to a very high price-to-earnings ratio and the lack of dividend support.

More about SRT Marine Systems

SRT Marine Systems is a global provider of maritime intelligence, surveillance and navigation safety solutions focused on maritime domain awareness. Its technologies are used by coast guards, fisheries authorities, ports and both commercial and leisure vessel operators to support intelligence-led maritime operations and enhance navigation safety and security.

Trellus Health plc (LSE:TRLS), which joined AIM in 2021, operates the Trellus Elevate® digital platform, combining data analytics, resilience-based training and expert support to help patients manage chronic conditions while reducing expensive hospital and emergency care usage. The company primarily focuses on chronic gastrointestinal diseases with significant mental health impacts and believes its methodology can be expanded into additional therapeutic areas over time.

Funding Constraints Force Strategic Review and Trading Suspension

The company said recent cost-cutting initiatives have extended its cash runway only until mid-June 2026. Trellus had previously reduced monthly cash burn to roughly $300,000 and relied on short-term financial support measures to preserve liquidity.

However, with long-term funding still unresolved and access to an existing convertible loan note facility limited by current market conditions, the company has engaged restructuring advisers to evaluate strategic alternatives. Options under consideration include the potential sale of its U.S. subsidiary. Trellus has also requested the suspension of trading in its AIM-listed shares due to limited working capital and ongoing financial uncertainty.

Weak Financial Position Continues to Weigh on Outlook

Trellus Health’s outlook remains constrained by weak financial performance, including substantial ongoing losses, negative free cash flow and declining equity levels, despite the benefit of operating without debt.

Technical indicators remain one of the few supportive factors, with the shares previously showing strong momentum above major moving averages. Nevertheless, valuation remains pressured by the company’s loss-making position and the absence of any indicated dividend yield.

More about Trellus Health PLC

Trellus Health plc is a healthcare technology business focused on value-based digital solutions for complex chronic conditions, particularly high-cost gastrointestinal diseases such as inflammatory bowel disease. Its Trellus Elevate® platform combines proprietary resilience-based methodologies, data analytics, technology tools and expert coaching to provide personalised whole-person condition management. The company also offers the Trellus TrialSet™ service for pharmaceutical industry partners.

Physiomics’ (LSE:PYC) recently appointed board has initiated a broad strategic review designed to improve operational efficiency, strengthen commercial execution and enhance long-term shareholder value. The company said it sees significant untapped potential in its scientific capabilities, industry partnerships and commercial pipeline, while also highlighting that existing cash resources are expected to provide runway into 2027.

Management added that the business intends to maintain its scientific standards while pursuing future growth opportunities.

Board Restructuring and Cost Discipline Form Part of Overhaul

As part of the strategic changes, directors will receive a portion of their remuneration in shares without increasing total board cash costs. The company also confirmed that its finance lead has transitioned into the role of executive finance director and company secretary.

The board stated that it has identified additional commercial opportunities that it believes can be pursued within current budget levels and is also considering further board appointments to strengthen governance. In addition, Physiomics rejected recent market speculation regarding exit payments, signalling confidence in a leaner and more commercially focused operating structure.

Financial Pressures Continue Despite Revenue Improvement

Physiomics’ outlook remains constrained by weak financial performance, with ongoing losses and continued cash burn outweighing the benefits of a low-debt balance sheet and a recovery in revenue during 2025.

Technical indicators are moderately supportive, with the shares trading above major moving averages and the MACD remaining positive. However, an elevated RSI suggests momentum may be becoming stretched. Valuation metrics remain neutral to weak given negative earnings and the absence of dividend support.

More about Physiomics

Physiomics plc is a UK-based specialist in mathematical modelling, data science and biostatistics for biotechnology and pharmaceutical clients involved in drug development and personalised medicine. Using modelling and simulation, bioinformatics and its proprietary Virtual Tumour technology, the company supports discovery, pre-clinical and clinical programmes for global customers including Merck KGaA, Astellas, Bicycle Therapeutics and Cancer Research UK.

Intertek (LSE:ITRK) has rejected a revised unsolicited, indicative and conditional takeover proposal from EQT that valued the company at £58 per share, with the board concluding that the offer materially undervalues the business and presents considerable execution risk. After consulting with shareholders, the board said it remains committed to delivering value independently and believes the proposal fails to reflect Intertek’s long-term growth potential.

Intertek Pushes Ahead With Strategic Break-Up Review

Intertek is continuing with its strategic review aimed at separating its Testing & Assurance and Energy & Infrastructure divisions, potentially through either a sale or demerger process. The company said a sales-led process for the Energy & Infrastructure arm has already attracted interest from potential buyers.

Management believes establishing two more focused ATIC businesses would unlock shareholder value through improved capital allocation, quicker execution and greater investment flexibility. The proposed separation is targeted for completion by mid-2027 and is expected to support stronger growth, margin expansion and enhanced shareholder returns.

Strong Business Fundamentals Offset by Technical Weakness

Intertek’s outlook continues to benefit from solid underlying operational performance, including stable growth, healthy margins and positive free cash flow generation. Valuation metrics also remain supportive, with the shares trading on a relatively low price-to-earnings ratio alongside a dividend yield of around 4%.

However, these positives are balanced against weaker technical indicators, with the stock trading below key moving averages and the MACD remaining negative. Investors are also monitoring increasing balance sheet and cash flow risk signals emerging during 2025, despite constructive guidance for 2026.

More about Intertek

Intertek Group plc is a global provider of Assurance, Testing, Inspection and Certification (ATIC) services. The company serves customers across sectors including consumer products, corporate assurance, health and safety, energy, infrastructure, minerals and transportation. Intertek focuses on science-based quality assurance solutions and operates through a decentralised model aligned to end markets, supported by a broad international presence.

Quantum Blockchain Technologies (LSE:QBT) has restarted its quantum computing research initiative focused on Bitcoin mining, bringing back the same research team from the University of Milan following a pause in development caused by limitations in available quantum hardware. The company said the renewed effort is intended to build on previous work and accelerate progress in an area it considers strategically important for the future efficiency of cryptocurrency mining.

Focus Remains on Quantum Hardware and SHA-256 Development

The programme will concentrate on monitoring advances in quantum computing hardware and algorithm development while utilising QBT’s proprietary quantum implementation of the SHA-256 hashing algorithm.

The company believes this technology will serve as a valuable benchmarking tool for assessing emerging quantum platforms. Management expects the capability could position QBT to respond rapidly to any technological breakthrough that makes quantum computing commercially practical for Bitcoin mining, potentially providing a long-term competitive edge.

Weak Financial Performance Continues to Weigh on Outlook

Quantum Blockchain Technologies’ outlook remains constrained by weak underlying financial performance, including limited revenue generation, persistent losses, negative equity and continued cash burn over multiple years. Technical indicators also remain negative, with the shares trading below major moving averages and the MACD signalling ongoing weakness.

Valuation support remains limited as the company continues to report negative earnings and does not currently offer a dividend yield.

More about Quantum Blockchain Technologies PLC

Quantum Blockchain Technologies Plc is an AIM-listed research, development and investment company focused on blockchain technologies, cryptocurrency mining and advanced blockchain-related applications. The company’s primary goal is to develop technology-driven Bitcoin mining methods and tools that it believes can significantly outperform conventional market approaches.